MedImmune strengthens immune-mediated cancer therapy portfolio with acquisition of Amplimmune
26 August 2013 | By AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune...